Skip to main content

Navigation principale

  • About
  • Team
  • Portfolio
  • Strategy
  • ESG
  • Testimonials
  • News
  • Contact

Secondary Navigation

  • Fr
  • En

Actualités

You are here

  • Home
  • Actualités
Logo Nuclidium

VIVES Partners joins Nuclidium AG’s €84M Series B financing

Post date
10/07/2025

Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals

Participation is

Read more
Novadip logo

Novadip and Cliniques universitaires Saint-Luc report positive results for compassionate use of NVD003 on four pediatric patients

Post date
10/07/2025

NVD003 is a bone grafting material developed to surgically treat patients with Congenital Pseudarthrosis of the Tibia, a rare and difficult-to-treat pediatric disease

Four young patients were treated

Read more
AWARD 2025

The Akkermansia Company (TAC) acquired by Danone

Post date
25/06/2025

VIVES Partners’ portfolio investment The Akkermansia Company (TAC) acquired by Danone

Acquisition of TAC’s gut microbiota product, with benefits for people at risk of cardiovascular disease

Read more
Novadip logo

Novadip receives RMAT designation for NVD003, its regenerative treatment for congenital pseudarthosis of the tibia

Post date
24/06/2025

Novadip is developing NVD003, an autologous therapy derived from adipose stem cells, as a potential single treatment to save limbs and restore mobility in patients with CPT.

The RMAT designation is

Read more

Novadip shares positive 12-month results from phase 1b/2a trial with NVDX3 in trauma

Post date
14/02/2025

At 12 months, 100% of participants with distal radius fractures treated in trial with NVDX3, an allogenic stem-cell derived bone graft material, demonstrated durable bone union

No adverse events

Read more

BiocSol secures additional €4.4M to develop its sustainable crop protection solutions

Post date
14/02/2025

BiocSol succeeds in its ambition to raise a total of €10M since inception to fast-track the development of its sustainable crop protection solutions - testament to the sector’s growing interest in its

Read more

Eligo Expands Investor Syndicate with Key Strategic Additions

Post date
17/12/2024

Eligo welcomes genetic medicines leader Bobby Gaspar as chair of its board of directors
Oct 1, 2024

  • Dr. Gaspar brings invaluable expertise to gene-editing pioneering company Eligo as it prepares

Read more
Team

Generare raises €5m to scale the discovery of new medicines and molecules hiding in microbes

Post date
17/12/2024

Generare raises €5m to scale the discovery of new medicines and molecules hiding in microbes

  • Generare uses a novel cloning technique to break down microbial DNA and accelerate the discovery of
Read more
Team

BiocSol secures €5.2M seed funding to transform sustainable crop protection

Post date
20/11/2024

BiocSol secures €5.2M seed funding to transform sustainable crop protection with next generation microbial-based solutions, targeting total €10M in funding by year-end
 

  • Built on decade of research
Read more
atb therapeutics

ATB Therapeutics Raises €54 Million Series A Financing to Propel Innovative Antibody Payload Technology into Clinical Development

Post date
18/11/2024

ATB Therapeutics Raises €54 Million Series A Financing to Propel Innovative Antibody Payload Technology into Clinical Development
• Financing co-led by EQT Life Sciences and MRL Ventures Fund (MRLV

Read more
VIVES IUF

VIVES IUF Fund raises additional €5M capital from Luxembourg Future Fund 2

Post date
13/09/2024

 

  • New investment from Luxembourg Future Fund 2 brings total funding to €75M, well above original target
  • Deal underlines VIVES’ know-how in connecting academic research and innovative projects with
Read more
Brightflow Raises €16.5M in Series A Financing Round A

Brightflow Raises €16.5M in Series A Financing Round

Post date
10/09/2024

Funding will go towards development of first long-term percutaneous right ventricular assist device

Paris, France, September 10, 2024 – Brightflow SAS, a privately held pioneer in the field of long

Read more

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Next page ››
  • Last page Last »
 

VIVES Funds

VIVES Partners
Chemin du Stocquoy, 1
1300 Wavre
Belgium

Email
info@vivesfund.com
GSM
+32 472 206 355

Contact

Please note that VIVES only invests in companies located in Europe.
Maximum 5 files.
256 MB limit.
Allowed types: txt, rtf, pdf, doc, docx, odt, ppt, pptx, odp, xls, xlsx, ods.
Lire la politique générale de protection des données personnelles.

VIVES is a multi-sector technology fund that invests in spin-offs from UCLouvain and start-ups in Belgium and neighboring countries. The fund has the ability to invest at different stages of a company's development: seed, start-up and growth.

Menu Pied de page

  • Privacy policy & cookies
  • Terms & conditions
  • © 2025 All rights reserved.
  • Website by Visible